Lidakol 10 percent n-docosanol cream data

LDAKA reported additional data from its Phase III U.S./Canadian trials of Lidakol to treat recurrent oral herpes. In two studies of early treatment of herpes episodes before the development of a blister, patients experienced complete elimination of pain in 2.6 and 4 days, respectively, compared to historical data of 6 days for untreated disease.

The third study looked at treatment with Lidakol after blisters had appeared. The compound was ineffective in this trial, with healing times averaging 6.9 days from initiation of treatment versus 8-9 days for untreated episodes. The company said this was expected, because Lidakol's mechanism of action is to interfere with infection when herpes viruses begin to enter target cells. ...